Eli Lilly and Company

Novo Nordisk A/S

They are different from the already-hit Wegovy and Zepbound

Lilly and Novo simultaneously filed applications for approval of new obesity drugs

Late-stage trial data also show a potent effect in knee osteoarthritis

Eli Lilly's new drug has helped you lose almost 30% of your weight. It's her weapon of choice against Ozempic

Structure Therapeutics Inc.

Shares of Structure Therapeutics more than doubled on Monday, December 8, closing near $70 apiece, with <a href="https://finance.yahoo.com/quote/GPCR/">the company’s market capitalization</a> rocketing above $4.2 billion. This followed mid-stage trial results for its experimental oral obesity drug, aleniglipron, which <a href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access">delivered</a>&nbsp;greater weight loss than a <a href="https://lilly.mediaroom.com/2025-08-07-Lillys-oral-GLP-1,-orforglipron,-delivers-weight-loss-of-up-to-an-average-of-27-3-lbs-in-first-of-two-pivotal-Phase-3-trials-in-adults-with-obesity">competing pill</a> under development by Eli Lilly. Analysts say the stock may have further upside, particularly if a major player moves to acquire the company.

Structure shares double after 'near-homerun' obesity pill data

Meta Platforms, Inc.

NVIDIA Corporation

Alphabet Inc.

Apple Inc.

Meta discusses a multi-billion dollar deal to buy Google processors, which increases competition for Nvidia and provokes volatility in its shares. Apple, on the back of a strong iPhone 17 launch and a new round of upgrades, could overtake Samsung to become the global smartphone market leader for the first time in 14 years. Fintech giant Revolut cemented its status as Europe's most expensive startup. The main events of November 24-28 are in our review<b>. </b>

Highlights of the week: Apple rushes to the top, Google, Meta and Burry challenge Nvidia

HeartBeam, Inc.

Tilray Brands, Inc.

Corsair Gaming, Inc.

Robinhood Markets, Inc.

Li Auto Inc.

Deere & Company

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: trading will be held in hibernation mode

HP Inc.

Urban Outfitters, Inc.

Dell Technologies Inc.

Morning in New York: buyers are back in the majority

Pfizer Inc.


The White House also secured reductions in the cost of Wegovy and Pfizer's cancer drug

Novo will cut the price of Ozempic by 71% for older Americans. This will hinder revenue growth

Novo Nordisk reported that its new experimental drug helped people lose weight and improve blood sugar levels in trials. The positive news contributed to the growth of the company's quotations by almost 5%. However, the shares of the Ozempic manufacturer have fallen in price by about 50% this year. Is it worth buying them in hopes of a reversal?

A new drug from the creator of Ozempic has helped people lose weight. Is it time to buy stocks?

Alibaba Group Holding Limited

Morning in New York: macro statistics will set the trading vector

The failure of a trial of a tablet version of Ozempic against Alzheimer's disease has come as a blow to Danish pharmaceutical manufacturer Novo Nordisk. The results showed no slowing of symptoms, and the company refused to extend the trial. Analysts note: it was one of the few opportunities for Novo to quickly strengthen its position amid increasing competition. The company's shares collapsed in Copenhagen by 12.4%, falling to their lowest level since July 2021.

Ozempic's failed Alzheimer's trial collapses Novo shares to lowest since 2021

The company is starting to resemble the tech giants from "The Magnificent Seven" again, analysts said

Eli Lilly became the first pharma giant to be capitalized at $1 trillion. What's next?

LifeMD, Inc.

Shares of telemedicine platform LifeMD <a href="https://finance.yahoo.com/quote/LFMD/">plunged</a>&nbsp;25% in early trading this morning, November 18. The company’s quarterly results came in weaker than Wall Street expected, and the management also lowered its revenue outlook for the year. The stock was not supported even by an agreement with Novo Nordisk that LifeMD <a href="https://ir.lifemd.com/press-release-details.php?newsId=3189112#:~:text=%D1%8D%D1%82%D0%BE%20%D1%81%D0%B0%D0%BC%D0%B0%D1%8F%20%D0%BD%D0%B8%D0%B7%D0%BA%D0%B0%D1%8F%20%D1%86%D0%B5%D0%BD%D0%B0%20%D0%BD%D0%B0%D0%BB%D0%B8%D1%87%D0%BD%D1%8B%D0%BC%D0%B8%20%D0%B2%20%D1%81%D1%82%D1%80%D0%B0%D0%BD%D0%B5%20%E2%80%94%20%D0%B7%D0%B0%20%D0%B4%D0%B2%D0%B5%20%D0%BF%D0%BE%D0%BA%D1%83%D0%BF%D0%BA%D0%B8%20%D0%B4%D0%BB%D1%8F%20%D0%BD%D0%BE%D0%B2%D1%8B%D1%85%20%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2.">announced</a>&nbsp;earlier in the day yesterday. Under its terms, the platform will sell the pharma giant’s best-selling drugs Wegovy and Ozempic at “the lowest cash-pay pricing available nationwide.”